Logos Global Management LP
SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.65B2026 Q3+ $201.6M options (notional, not included)
Positions72
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.44.9%
What Changed This Quarter?
Top Holdings
PRAX
Praxis Precision Medicines
6.7%
RVMD
Revolution Medicines
6.6%
IDYA
IDEAYA Biosciences
5.9%
ERAS
Erasca
4.7%
ABVX
Abivax S.A.
4.6%
CGON
CG Oncology
3.7%
IRON
Disc Medicine
3.6%
BNTX
BioNTech
3.4%
New / Increased
29 new · 10 increased
MDGLNEW
Madrigal Pharmaceuticals
2.7%
ERASCALLNEW
Erasca
2.0%
NBIXNEW
Neurocrine Biosciences
1.9%
AXSMNEW
Axsome Therapeutics
1.7%
APMDNEW
Apnimed
1.3%
PRAX
Praxis Precision Medicines
6.7%
+63.5%
ELVN
Enliven Therapeutics
2.7%
+132.3%
GPCR
Structure Therapeutics
1.7%
+100.0%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.